What's breaking now, across thousands of outlets.
(RTTNews) - Tuesday, uniQure (QURE) reported new data showing its investigational gene therapy AMT-130 continued to slow measures of Huntington's disease progression in patients followed for up to 48 months.
We haven't written up this one. Nasdaq Markets has the full story — the link below goes straight to it.
The Ministry of Health has outlined four key medical tests vital for maintaining heart health, including blood pressure and cholesterol monitoring.
Fresenius Kabi will sell biosimilars directly to employers. To accomplish that, the drugmaker is working with Eversana-owned Waltz Health, which runs a marketplace that helps employers shop for better…
Drugmakers and investors have ramped up their spending and R&D attention on autoimmune diseases in recent years, with a proliferation of bispecific T cell engagers, various approaches to CAR-T cell…
Infections caused by viruses, bacterium and parasites caused an estimated 2.3 million new cancer cases in 2024, with low- and middle-income countries bearing most of the burden.
The data collected will be uploaded on Blood Banks Management Software (BBMS) to prevent commercialisation, spread of diseases, and to check irregularities; overall, 246 blood banks exist in the State
The wealthy and ultra-wealthy are spending more on longevity care than ever before. Should you invest your money into similar therapeutics? Experts weigh in.
